Phase 4
Completed N=16
Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia
Tachycardia, Ventricular
Source: ClinicalTrials.gov NCT01901575 ↗
Enrolled (actual)
16
Serious AEs
—
Results posted
Dec 2014
Primary outcomePrimary: Inhibition of Idiopathic Ventricular Tachycardia
Summary
Determine effects of remifentanil conscious sedation in patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent premature ventricular contractions (PVCs) of non-ischemic origin
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Inhibition of Idiopathic Ventricular Tachycardia |
— | — |
| PRIMARY PVC Suppression With Remifentanil Sedation |
2 | 0.05 |
Eligibility Criteria
Inclusion Criteria
- Patients scheduled to undergo EP studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin
- Patients between 18 and 65
- ASA 1-3
Exclusion Criteria
- ASA 4 and 5
- Age 18 and 65
Data sourced from ClinicalTrials.gov (NCT01901575). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.